Bio-Thera(SH:688177)2022-10-26 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥152,791,176.23, representing a year-on-year increase of 76.17%[5] - The net profit attributable to shareholders for the same period was -¥86,491,752.30, with a year-to-date net profit of -¥255,621,854.06[5] - Total operating revenue for the first three quarters of 2022 was CNY 381,785,964.28, a decrease of 8.06% compared to CNY 415,396,572.73 in the same period of 2021[37] - The company reported a net loss of CNY 1,636,444,492.97 for the period, worsening from a loss of CNY 1,380,822,638.91 in the previous year[35] - The net profit for the third quarter was -255,621,854.06 RMB, compared to -111,824,394.81 RMB in the same period last year, indicating a significant increase in losses[42] - The total comprehensive income attributable to the parent company was -255,446,268.88 RMB, compared to -111,839,232.53 RMB in the previous year[45] - Basic and diluted earnings per share were both -0.62 RMB, compared to -0.27 RMB in the same quarter of the previous year[45] Research and Development - Research and development expenses totaled ¥155,665,540.09 in Q3 2022, accounting for 101.88% of operating revenue, a decrease of 65.03 percentage points compared to the previous year[8] - Research and development expenses for the first three quarters of 2022 were CNY 422,090,457.76, up from CNY 372,935,102.68, indicating a 13.2% increase year-over-year[41] - The company plans to continue focusing on R&D to drive future growth despite current financial challenges[41] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,349,889,374.33, down 10.23% from the end of the previous year[8] - Total assets decreased to CNY 2,349,889,374.33 from CNY 2,617,782,079.77, a decline of 10.24%[35] - Total liabilities decreased slightly to CNY 517,823,433.50 from CNY 530,269,870.06, a reduction of 2.6%[35] - Owner's equity decreased from CNY 2,089,178,501.28 to CNY 1,833,796,744.39, a decline of approximately 12.2%[64] Cash Flow - The cash flow from operating activities for the year-to-date was -¥266,574,644.11, indicating a decrease in cash inflow from licensing revenue compared to the previous year[8] - Cash flow from operating activities for the first nine months was -266,574,644.11 RMB, worsening from -132,701,105.63 RMB year-over-year[49] - Cash inflow from investment activities was 3,128,278,575.33 RMB, up from 2,558,185,810.50 RMB in the previous year[55] - Cash outflow from investment activities totaled 3,508,322,117.14 RMB, compared to 2,201,646,828.96 RMB in the same period last year[55] - The net cash flow from financing activities was -32,422,859.82 RMB, compared to 29,765,500.00 RMB in the previous year[55] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,234[16] - The top shareholder, Zhuhai Jifu Qiheng Medical Investment Partnership, holds 21,499,471 shares, representing a significant portion of the company's equity[22] - The company reported a total of 159,990,270 shares held by Guangzhou Qixi Group, indicating a strong control over the company[21] - The report indicates that the company has not issued any new shares during the quarter, maintaining the existing share structure[21] Future Outlook - The company plans to continue focusing on product sales and expanding its market presence in the upcoming quarters[15] - The company has not provided any specific guidance for future performance in the upcoming quarters[26] - There are no new product launches or technological advancements reported in this quarter[26] - The company has not announced any market expansion or acquisition strategies during this reporting period[26] - The financial report does not indicate any significant changes in the management or operational strategies[26] - The company has not highlighted any risks or challenges faced during the quarter that could impact future performance[26]